openPR Logo
Press release

Global Janus Kinase Inhibitors Market Surges at 8.4% CAGR Through 2032 | Eli Lilly and Company., Bristol Myers Squibb company., GSK Plc., Pfizer Inc., Incyte., AbbVie Inc., Astellas Pharma Inc

04-11-2025 11:18 AM CET | Health & Medicine

Press release from: DataM Intelligence 4 Market Research LLP

Janus Kinase Inhibitors Market

Janus Kinase Inhibitors Market

The latest report published by DataM Intelligence highlights the growth prospects of Janus Kinase (JAK) Inhibitors market. The industry expansion is majorly driven by developments in technology across the globe.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/janus-kinase-(jak)-inhibitors-market?ca

The global Janus Kinase (JAK) Inhibitors market reached US$ 13.23 billion in 2023 and is expected to reach US$ 29.76Billion by 2032, growing at a CAGR of 8.4% during the forecast period 2024-2032.

Janus Kinase (JAK) inhibitors are targeted medications that block specific enzymes involved in the inflammatory signaling pathways of the immune system. Used to treat autoimmune and inflammatory conditions like rheumatoid arthritis, psoriasis, and ulcerative colitis, JAK inhibitors help reduce inflammation, alleviate symptoms, and improve patient outcomes.

Competitive Evaluation:

Companies covered in this report are Eli Lilly and Company., Bristol Myers Squibb company., GSK Plc., Pfizer Inc., Incyte., AbbVie Inc., Astellas Pharma Inc, LEO Pharma A/S, Torii Pharmaceutical Co.,Ltd, and Sobi, Inc.

The Janus Kinase (JAK) Inhibitors Market analysis identifies a number of major market players. It enables companies to understand the strategies and partnerships used by other industry players to combat market competition. The comprehensive market report provides a fascinating microscopic look at the market. Corporations can detect the footprints of manufacturers by learning about demand, the global price of manufacturers, and the global benefit of manufacturing companies.

Key Development

In July 2024, the FDA approved LEQSELVI (deuruxolitinib), an oral JAK inhibitor by Sun Pharma, for adults with severe alopecia areata at an 8 mg tablet dosage. In September 2023, GSK's OJJAARA (momelotinib) received FDA approval for treating myelofibrosis patients with anemia. This once-daily oral JAK1/JAK2 and ACVR1 inhibitor addresses anemia, constitutional symptoms, and splenomegaly.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/janus-kinase-(jak)-inhibitors-market?ca

Janus Kinase (JAK) Inhibitors Market Segments

The report covers the segmentation of the market into different segments based on various classifications such as applications, end users, product types, and others. The segmentation is divided into two sections, one for development and the other for different roles, needs, and behaviors.

By Product: Abrocitinib, Baricitinib, Delgocitinib, Fedratinib, Ruxolitinib,
Tofacitinib, Upadacitinib, Others
By Mechanism: Reversible Inhibitors, Irreversible Inhibitors
By Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis,
Eczema, Alopecia Areata, Myelofibrosis, Ulcerative Colitis, Graft-Versus-Host Disease (GVDH), Polycythemia Vera, Others

Regional Assessment:

Regional analysis includes segmentation based on the geography that accentuates the recent and future demand for Janus Kinase (JAK) Inhibitors market across North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The study also focuses on the demand for each application segment over all the prominent regions.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

In terms of geographical analysis, Janus Kinase (JAK) Inhibitors Market report provides an in-depth view of:-

∎ Regional level break-up
∎ Leading growth rates
∎ Countries with the largest market share
∎ Market factors
∎ Latest developments
∎ Industry challenges
∎ Regulatory policies
∎ Player strategies

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/janus-kinase-(jak)-inhibitors-market?ca

This report provides a 360-degree synopsis of the competitive scenario of the Janus Kinase (JAK) Inhibitors industry. It has enormous awareness joined to the ongoing item and technical improvements in the business sector. It has a thorough analysis of the impact of the potential future development of these headways, a wide-ranging review of those extensions available for future growth.

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Browse More Reports: https://www.datamintelligence.com/research-report/janus-kinase-(jak)-inhibitors-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

The latest report published by DataM Intelligence highlights the growth prospects of Janus Kinase (JAK) Inhibitors market. The industry expansion is majorly driven by developments in technology across the globe.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/janus-kinase-(jak)-inhibitors-market?ca

The global Janus Kinase (JAK) Inhibitors market reached US$ 13.23 billion in 2023 and is expected to reach US$ 29.76Billion by 2032, growing at a CAGR of 8.4% during the forecast period 2024-2032.

Janus Kinase (JAK) inhibitors are targeted medications that block specific enzymes involved in the inflammatory signaling pathways of the immune system. Used to treat autoimmune and inflammatory conditions like rheumatoid arthritis, psoriasis, and ulcerative colitis, JAK inhibitors help reduce inflammation, alleviate symptoms, and improve patient outcomes.

Competitive Evaluation:

Companies covered in this report are Eli Lilly and Company., Bristol Myers Squibb company., GSK Plc., Pfizer Inc., Incyte., AbbVie Inc., Astellas Pharma Inc, LEO Pharma A/S, Torii Pharmaceutical Co.,Ltd, and Sobi, Inc.

The Janus Kinase (JAK) Inhibitors Market analysis identifies a number of major market players. It enables companies to understand the strategies and partnerships used by other industry players to combat market competition. The comprehensive market report provides a fascinating microscopic look at the market. Corporations can detect the footprints of manufacturers by learning about demand, the global price of manufacturers, and the global benefit of manufacturing companies.

Key Development

In July 2024, the FDA approved LEQSELVI (deuruxolitinib), an oral JAK inhibitor by Sun Pharma, for adults with severe alopecia areata at an 8 mg tablet dosage. In September 2023, GSK's OJJAARA (momelotinib) received FDA approval for treating myelofibrosis patients with anemia. This once-daily oral JAK1/JAK2 and ACVR1 inhibitor addresses anemia, constitutional symptoms, and splenomegaly.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/janus-kinase-(jak)-inhibitors-market?ca

Janus Kinase (JAK) Inhibitors Market Segments

The report covers the segmentation of the market into different segments based on various classifications such as applications, end users, product types, and others. The segmentation is divided into two sections, one for development and the other for different roles, needs, and behaviors.

By Product: Abrocitinib, Baricitinib, Delgocitinib, Fedratinib, Ruxolitinib,
Tofacitinib, Upadacitinib, Others
By Mechanism: Reversible Inhibitors, Irreversible Inhibitors
By Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis,
Eczema, Alopecia Areata, Myelofibrosis, Ulcerative Colitis, Graft-Versus-Host Disease (GVDH), Polycythemia Vera, Others

Regional Assessment:

Regional analysis includes segmentation based on the geography that accentuates the recent and future demand for Janus Kinase (JAK) Inhibitors market across North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The study also focuses on the demand for each application segment over all the prominent regions.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

In terms of geographical analysis, Janus Kinase (JAK) Inhibitors Market report provides an in-depth view of:-

∎ Regional level break-up
∎ Leading growth rates
∎ Countries with the largest market share
∎ Market factors
∎ Latest developments
∎ Industry challenges
∎ Regulatory policies
∎ Player strategies

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/janus-kinase-(jak)-inhibitors-market?ca

This report provides a 360-degree synopsis of the competitive scenario of the Janus Kinase (JAK) Inhibitors industry. It has enormous awareness joined to the ongoing item and technical improvements in the business sector. It has a thorough analysis of the impact of the potential future development of these headways, a wide-ranging review of those extensions available for future growth.

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Browse More Reports: https://www.datamintelligence.com/research-report/janus-kinase-(jak)-inhibitors-market

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Janus Kinase Inhibitors Market Surges at 8.4% CAGR Through 2032 | Eli Lilly and Company., Bristol Myers Squibb company., GSK Plc., Pfizer Inc., Incyte., AbbVie Inc., Astellas Pharma Inc here

News-ID: 3966906 • Views:

More Releases from DataM Intelligence 4 Market Research LLP

United States Natural Caffeine Market: Supply Chain & Coffee Price Volatility | Major Companies - SHRI AHIMSA NATURALS LIMITED, Applied Food Sciences (AFS), Botanic Healthcare, Natura Vitalis
United States Natural Caffeine Market: Supply Chain & Coffee Price Volatility | …
Market Size and Forecast: Global Natural Caffeine Market reached US$ 3.4 billion in 2023 and is expected to reach US$ 5.27 billion by 2031, growing with a CAGR of 5.6% during the forecast period 2024-2031. The Natural Caffeine Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and
United States Sustainable Pharmaceutical Packaging Market: 12.7% CAGR to US$ 316.05 Billion By 2033 | Top Most Keyplayers - Amcor plc, Berry Global Inc., Gerresheimer AG, WestRock Company
United States Sustainable Pharmaceutical Packaging Market: 12.7% CAGR to US$ 316 …
Market Size and Forecast: Sustainable Pharmaceutical Packaging Market size reached US$ 91.94 Billion in 2024 and is expected to reach US$ 316.05 Billion by 2033, growing at a CAGR of 12.7% during the forecast period 2025-2033, according to DataM Intelligence report. The Global Sustainable Pharmaceutical Packaging Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM
United States Ultra High Performance Concrete (UHPC) Market 2025 | Infrastructure Innovation & Sustainability Drive Global Growth
United States Ultra High Performance Concrete (UHPC) Market 2025 | Infrastructur …
DataM Intelligence has published a new research report on "Ultra High Performance Concrete Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Pre-packaged UHPC is priced at over
United States Automotive Artificial Intelligence (AI) Industry Sector Growth to 2031 | Leading Companies - German Autolabs, Raven, Argo AI, Deepscale, Cisco
United States Automotive Artificial Intelligence (AI) Industry Sector Growth to …
DataM Intelligence has published a new research report on "Automotive Artificial Intelligence Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample PDF Of This

All 5 Releases


More Releases for JAK

Key Trends Influencing the Growth of the Janus Kinase (JAK) Inhibitors Market in …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Janus Kinase (JAK) Inhibitors Market Through 2025? The market size of Janus Kinase (JAK) inhibitors has experienced a quick growth over the recent years. The market, which stood at $20.19 billion in 2024, is projected to see a rise to $23.56 billion
Vitiligo Treatment Innovation Accelerates with JAK Inhibitors and Novel Immunoth …
Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving the Vitiligo treatment landscape. Let's explore how this will impact the Vitiligo treatment landscape. DelveInsight's "Vitiligo Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights on the vitiligo pipeline, showcasing a dynamic landscape of emerging therapies and a promising outlook for patients suffering from this challenging autoimmune skin
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period. The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing
Leading Growth Driver in the Janus Kinase (JAK) Inhibitors Market in 2025: Surgi …
Which drivers are expected to have the greatest impact on the over the janus kinase (jak) inhibitors market's growth? The escalating occurrences of autoimmune disorders are anticipated to stimulate the expansion of the Janus kinase (JAK) inhibitors market. These disorders involve a broad spectrum of abnormalities within the immune system where it erroneously attacks and destroys healthy cells, tissues, and organs. The therapeutic benefits of Janus Kinase (JAK) inhibitors for autoimmune
Janus Kinase (JAK) Inhibitor Pipeline Therapeutics Assessment Report 2024 (Updat …
DelveInsight's, "Janus Kinase Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Janus Kinase
Janus kinase (JAK) Inhibitors Competitive Landscape Report 2024
DelveInsight's, "Janus kinase inhibitors Competitive landscape 2024" report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Janus kinase Inhibitors Report • DelveInsight's Janus kinase Inhibitors report depicts a robust space